🇺🇸 ARIPiprazole 30 MG in United States

16 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Condition Aggravated — 3 reports (18.75%)
  2. Hypotension — 3 reports (18.75%)
  3. Dysphagia — 2 reports (12.5%)
  4. Muscle Spasms — 2 reports (12.5%)
  5. Acute Respiratory Failure — 1 report (6.25%)
  6. Ageusia — 1 report (6.25%)
  7. Akathisia — 1 report (6.25%)
  8. Alopecia — 1 report (6.25%)
  9. Atrial Fibrillation — 1 report (6.25%)
  10. Blood Creatine Phosphokinase Increased — 1 report (6.25%)

Source database →

ARIPiprazole 30 MG in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is ARIPiprazole 30 MG approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for ARIPiprazole 30 MG in United States?

Ain Shams University is the originator. The local marketing authorisation holder may differ — check the official source linked above.